Serum Uric Acid, Influence Of Sacubitril–Valsartan, And Cardiovascular Outcomes In Heart Failure Wit

Researchers examined whether serum uric acid (SUA) has prognostic value on outcomes in heart failure (HF) with preserved ejection fraction (HFpEF), and if sacubitril–valsartan decreases SUA as well as the use of SUA‐related therapies. The participants were 4,795 in total and were selected from the Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin‐receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON‐HF) trial. Findings revealed that adverse outcomes in HFpEF were independently predicted by serum uric acid. Reduction in SUA and the initiation of related therapy was reported in relation to sacubitril–valsartan vs valsartan. Improved outcomes were observed in correlation with decreases in SUA.

​

Source